CN101479268B - 2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用 - Google Patents

2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用 Download PDF

Info

Publication number
CN101479268B
CN101479268B CN2007800239044A CN200780023904A CN101479268B CN 101479268 B CN101479268 B CN 101479268B CN 2007800239044 A CN2007800239044 A CN 2007800239044A CN 200780023904 A CN200780023904 A CN 200780023904A CN 101479268 B CN101479268 B CN 101479268B
Authority
CN
China
Prior art keywords
pain
disease
methoxyl group
amino
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800239044A
Other languages
English (en)
Chinese (zh)
Other versions
CN101479268A (zh
Inventor
爱德华·丹尼尔·萨沃里
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Biotechnology Ltd
Original Assignee
Cbt Development Ltd
Biovitrum AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cbt Development Ltd, Biovitrum AB filed Critical Cbt Development Ltd
Publication of CN101479268A publication Critical patent/CN101479268A/zh
Application granted granted Critical
Publication of CN101479268B publication Critical patent/CN101479268B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN2007800239044A 2006-06-27 2007-06-26 2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用 Expired - Fee Related CN101479268B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
SE0601397-3 2006-06-27
SE06013973 2006-06-27
SE0601397 2006-06-27
US83740206P 2006-08-11 2006-08-11
US60/837,402 2006-08-11
PCT/EP2007/056377 WO2008000744A2 (en) 2006-06-27 2007-06-26 2-0'-methyladen0sine derivatives and their use as agonists or antagonists of an adenosine receptor

Publications (2)

Publication Number Publication Date
CN101479268A CN101479268A (zh) 2009-07-08
CN101479268B true CN101479268B (zh) 2012-08-08

Family

ID=38573394

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800239044A Expired - Fee Related CN101479268B (zh) 2006-06-27 2007-06-26 2-0’-甲基腺苷衍生物及其用作制备腺苷受体的激动剂或拮抗剂的应用

Country Status (10)

Country Link
US (1) US7820811B2 (enExample)
EP (1) EP2081932A2 (enExample)
JP (1) JP2009541437A (enExample)
CN (1) CN101479268B (enExample)
AU (1) AU2007263727A1 (enExample)
BR (1) BRPI0713902A2 (enExample)
CA (1) CA2654371A1 (enExample)
NZ (1) NZ573307A (enExample)
RU (1) RU2009102536A (enExample)
WO (1) WO2008000744A2 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ573308A (en) * 2006-06-27 2012-02-24 Biovitrum Ab Publ Adenosine derivatives for the treatment of pain
WO2012048013A2 (en) * 2010-10-06 2012-04-12 Inhibitex, Inc. Phosphorodiamidate derivatives of guanosine nucleoside compounds for treatment of viral injections

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269574A2 (en) * 1986-11-27 1988-06-01 Nippon Zoki Pharmaceutical Co. Ltd. Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
EP0490818A1 (en) * 1990-12-07 1992-06-17 Sandoz Ltd. 6-cyclohexyl-2'-0-methyl-adenosine hydrate and uses thereof
EP0601322A2 (en) * 1992-10-27 1994-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Adenosindeaminase inhibitor

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5968914A (en) 1987-10-28 1999-10-19 Pro-Neuron, Inc. Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
WO1991006556A1 (en) * 1989-10-24 1991-05-16 Gilead Sciences, Inc. 2' modified oligonucleotides
US5877180A (en) 1994-07-11 1999-03-02 University Of Virginia Patent Foundation Method for treating inflammatory diseases with A2a adenosine receptor agonists
ES2194320T3 (es) 1997-06-03 2003-11-16 Itochu Techno Chem Inc Sustancias naturales antivirales o antitumorales y uso de las mismas.
US6576619B2 (en) 1999-05-24 2003-06-10 Cv Therapeutics, Inc. Orally active A1 adenosine receptor agonists
KR20050055630A (ko) 2002-06-28 2005-06-13 이데닉스 (케이만) 리미티드 플라비비리다에 감염 치료를 위한 1'-, 2'- 및 3'-변형된뉴클레오시드 유도체
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
GB0305153D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Identification of therapeutic compounds
GB0305150D0 (en) 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
GB0328323D0 (en) 2003-12-05 2004-01-07 Cambridge Biotechnology Ltd Synthesis of 2-substituted adenosines
KR20070004792A (ko) 2004-03-05 2007-01-09 캠브리지 바이오테크놀로지 리미티드 아데노신 수용체 작용제
NZ573308A (en) 2006-06-27 2012-02-24 Biovitrum Ab Publ Adenosine derivatives for the treatment of pain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0269574A2 (en) * 1986-11-27 1988-06-01 Nippon Zoki Pharmaceutical Co. Ltd. Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
EP0490818A1 (en) * 1990-12-07 1992-06-17 Sandoz Ltd. 6-cyclohexyl-2'-0-methyl-adenosine hydrate and uses thereof
EP0601322A2 (en) * 1992-10-27 1994-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Adenosindeaminase inhibitor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Jayson M. Rieger,et al..Design, Synthesis, and Evaluation of Novel A2A Adenosine Receptor Agonists.《J. Med. Chem.》.2001,第44卷(第4期),531-539. *
JaysonM.Rieger et al..Design
Suhaib M. Siddiqi,et al..Search for New Purine- and Ribose-Modified Adenosine Analogs as Selective Agonists and Antagonists at Adenosine Receptors.《J. Med. Chem.》.1995,第38卷(第7期),1174–1188. *

Also Published As

Publication number Publication date
RU2009102536A (ru) 2010-08-10
AU2007263727A1 (en) 2008-01-03
BRPI0713902A2 (pt) 2012-11-27
WO2008000744A3 (en) 2008-02-28
US20080009461A1 (en) 2008-01-10
WO2008000744A2 (en) 2008-01-03
EP2081932A2 (en) 2009-07-29
NZ573307A (en) 2012-02-24
CA2654371A1 (en) 2008-01-03
JP2009541437A (ja) 2009-11-26
US7820811B2 (en) 2010-10-26
CN101479268A (zh) 2009-07-08

Similar Documents

Publication Publication Date Title
Chandra et al. Fluorine-a small magic bullet atom in the drug development: perspective to FDA approved and COVID-19 recommended drugs
KR100401454B1 (ko) 신규한 ａ1 아데노신 수용체 작동약
CA2557285A1 (en) Adenosine receptor agonists
CN101479290A (zh) 新的2′,3′-亚甲基缩醛腺苷前药用作腺苷受体激动剂的前药
CN102058614A (zh) 腺苷受体激动剂在治疗中的用途
JP5042996B2 (ja) Ａ１アデノシンレセプターアゴニスト
KR102434764B1 (ko) 간 전송 항바이러스 전구체 약물 뉴클레오시드 시클로 포스페이트 에스테르 화합물 및 응용
EP2081946B1 (en) Adenosine derivatives for the treatment of pain
HK1048821A1 (en) Thiophene a2a receptor agonists
US7820811B2 (en) Pro-drugs of adenosine receptor agonists
CN109776544A (zh) 吡唑并[3,4-d]嘧啶类化合物及其制备方法和用途
AU672226B2 (en) 2-substituted adenosines with A-2 receptor affinity
HK1129109A (en) 2-0'-methyladenosine derivatives and their use as agonists or antagonists of an adenosine receptor
HK1129117A (en) Novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists novel 2',3'-methylidene acetyl adenosine prodrugs for use as prodrugs for adenosine receptor agonists
JP2004502780A (ja) アデノシン化合物及びそれを含む医薬組成物
HK1129228A (en) Therapeutic compounds
Jacobson 2012 Philip S. Portoghese Medicinal Chemistry Lectureship: Structure-Based Approaches to Ligands for G Protein-Coupled Adenosine and P2Y Receptors, From Small Molecules to Nanoconjugates
Tchilibon et al. J Med Chem. Author manuscript; available in PMC 2012 October 03. Published in final edited form as: J Med Chem. 2005 March 24; 48 (6): 1745–1758. doi: 10.1021/jm049580r.
JP2012102114A (ja) アデノシン受容体アゴニスト

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1129109

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: CBT DEVELOPMENT CO., LTD.

Free format text: FORMER OWNER: BIOVITRUM AB PUBL

Effective date: 20110316

C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: STOCKHOLM, SWEDEN TO: LONDON, UK

TA01 Transfer of patent application right

Effective date of registration: 20110316

Address after: London, England

Applicant after: Cambridge Biotechnology Ltd.

Address before: Stockholm

Applicant before: Biovitrum AB Publ

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120808

Termination date: 20130626

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1129109

Country of ref document: HK